|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Dual-expressor lymphoma is a form of DLBCL with overexpression of MYC and BCL2/BCL6.
|
28952038 |
2017 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In B-lymphoma cells, as a consequence of PCYT1A upregulation, MYC impeded lymphoma cells undergo a mitophagy-dependent necroptosis.
|
28686226 |
2017 |
|
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
There were 47 DTHLs, 36 cases with MYC and BCL2 and/or BCL6 extra signals (ES) and/or rearrangements (ES group, excludes DTHLs), 9 with MYC rearrangements only (single-hit lymphoma), and 95 with no MYC abnormalities (NM).
|
28614202 |
2017 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We undertook this study to assess MYC protein expression in a large cohort of pediatric lymphomas, sarcomas, and other SRBCT.
|
28521631 |
2017 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Thirty-four MYC-R lymphoma cases were studied: 21 treated with R-CHOP and 13 treated with BURKIMAB.
|
28648593 |
2017 |
|
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma.
|
27717585 |
2017 |
|
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
High-grade B-cell lymphomas (HGBLs) with MYC and BCL2 and/or BCL6 rearrangements, so-called "double-hit" lymphomas (HGBL-DH), are aggressive lymphomas that form a separate provisional entity in the 2016 revised World Health Organization Classification of Lymphoid Tumors.
|
27821509 |
2017 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Real-time polymerase chain reaction showed C-MYC mRNA expression in lymphoma-type and acute-type samples were significantly higher than in smoldering-type (P<0.01).
|
28498285 |
2017 |
|
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The low incidence of MYC translocations in DLBCL makes the genetic study of all these lymphomas cumbersome.
|
28288039 |
2017 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In total, 76 patients with diffuse large B-cell lymphoma had MYC extra copies including 43 cases of double or triple extra copy lymphoma; 105 patients had diffuse large B-cell lymphoma with MYC-R including 56 double- or triple-hit lymphoma; and 482 diffuse large B-cell lymphoma patients had no MYC abnormality (MYC normal).
|
28776574 |
2017 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
More recently, MYC rearrangement with multiple copies/gain of BCL2 or multiple copies/gain of MYC with a BCL2 rearrangement have been described and exhibit a very similar clinical course to conventional double-hit lymphomas.
|
27391453 |
2016 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Indeed, previous studies using gene-targeted mice revealed that BCL-XL, but surprisingly not BCL-2, is critical for the development of c-MYC-induced pre-B/B lymphomas.
|
26962682 |
2016 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Recognition and proper management of patients with MYC-altered lymphomas is crucial to improving patient outcomes.
|
26983958 |
2016 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we demonstrate that coordinated targeting of rDNA transcription and PI3K-AKT-mTORC1-dependent ribosome biogenesis and protein synthesis provides a remarkable improvement in survival in MYC-driven B lymphoma.
|
26490423 |
2016 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
MYC translocations occurred as single hit (only MYC rearranged, 63%) or multiple hit lymphoma (37%) and presented as acute leukemia (AL) (14%), Burkitt lymphoma (30%), chronic lymphocytic leukemia (CLL) (21%) or other mature B-cell neoplasms (35%).
|
27810071 |
2016 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In our patient series, we confirm the dismal prognosis of MYC+ lymphoma patients.
|
26820684 |
2016 |
|
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Double- and triple-hit lymphomas (DHL/THL) are aggressive B-cell neoplasms characterized by translocation of MYC with concurrent BCL2 and/or BCL6 translocation.
|
26892631 |
2016 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Most of the refractory patients exhibit double-hit lymphoma (MYC-BCL2 rearrangement) or double-protein-expression lymphoma (MYC-BCL2 hyperexpression) which have a more aggressive clinical picture.
|
27913503 |
2016 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Of note, expressions of MCT1 and MCT2 were each significantly elevated in MYCN-amplified neuroblastomas and C-MYC-overexpressing lymphomas than in tumors without MYC overexpression, correlating with poor prognosis and unfavorable patient survival.
|
26434591 |
2016 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Here, we report that the Zn(2+)-finger transcription factor ASCIZ (ATMIN, ZNF822) synergizes with MYC to activate the expression of dynein light chain (DYNLL1, LC8) in the murine Eμ-Myc model of lymphoma.
|
26832406 |
2016 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We show furthermore that BMAL1 expression levels correlate inversely with MYC levels in 102 human lymphomas.
|
27339797 |
2016 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Herein we summarize the unique biological behavior of double and triple hit lymphomas focusing on the coordinated network of pathways that enable cancer cells to tolerate the oncogenic stress imposed by the co-expression of MYC, BCL2 and BCL6.
|
27419806 |
2016 |
|
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The mean IHC score among lymphomas with MYC rearrangements was 80%, but with a large range of scores (20%-100%).
|
26834124 |
2016 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Oncogene MYC is deregulated in many human cancers, especially in lymphoma.
|
25692307 |
2015 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings suggest that co-inhibition of MYC and BCL2 signaling is a promising therapeutic strategy for patients with DHL/THL lymphomas.
|
25916698 |
2015 |